MedTrace Logo

Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine. .

NCT04773886 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-03-16

No results posted yet for this study

Summary

The aim of this study was to clinically and radiographically evaluate the effectiveness of MTA, Biodentine, Platelet Rich Fibrin along with Mineral Trioxide Aggregate and Platelet Rich Fibrin along with Biodentine as pulpotomy medicament in patients with pulpitis.

Conditions

  • Pulpitis - Irreversible

Interventions

DRUG

Mineral trioxide aggregate

Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent

DRUG

Biodentine

Vital Pulpotomy will be done using Biodentine as pulp capping agent

BIOLOGICAL

Platelet rich fibrin

10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit. The product obtained after centrifugation consisted of three layers: * Acellular platelet plasma- top most layer * Platelet rich fibrin -middle layer * Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece

Sponsors & Collaborators

  • Maharishi Markendeswar University (Deemed to be University)

    lead OTHER

Principal Investigators

  • surinder sachdeva, M.D.S. · PROFESSOR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-03-12
Completion
2021-03-12
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04773886 on ClinicalTrials.gov